A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis-Reference-Cited by-同舟云学术

A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis

Published:2010-07 Issue:1 Volume:56 Page:29-37
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Jakubowski Joseph A,Li Ying G,Small David S,Payne Christopher D,Tomlin Molly E,Luo Junxiang,Winters Kenneth J

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference26 articles.

1. 3rd, Furman MI, et al. Measuring antiplatelet drug effects in the laboratory.;Harrison;Thromb Res,2007

2. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.;Jakubowksi;Thromb Haemost,2008

3. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention.;van Werkum;J Thromb Haemost,2006

4. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.;Varenhorst;Am Heart J,2009

5. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function.;Cattaneo;Semin Thromb Hemost,2009

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Dual Antiplatelet Therapy with the Routine Use of Prasugrel for Flow Diversion of Cerebral Unruptured Aneurysms;Clinical Neuroradiology;2023-10-17

2. Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients;Vascular Health and Risk Management;2023-01

3. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study;Journal of Stroke and Cerebrovascular Diseases;2022-07

4. Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention;Journal of International Medical Research;2022-04

5. Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y 12 receptor between selatogrel and oral P2Y 12 antagonists;CPT: Pharmacometrics & Systems Pharmacology;2021-05-30